Small Cap Feast

Small Cap Feast – 21 May 2020

Dish of the Day:

No Joiners Today

 

Off the Menu:

No Leavers Today

 

What’s Cooking in the IPO Kitchen?

The pantry is empty

 

Breakfast Buffet

Oncimmune 100p £63.5m (ONC.L)

The global immunodiagnostics group today announces that it has signed a foothill contract to utilise the Company’s Early CDT Lung panel to detect incident lung cancer cases in a screening setting. With one of the world’s largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting. Oncimmune  expects this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.

 

Randall & Quilter 135p £288m (RQIH.L)

The non-life global specialty insurance company focusing on the Program Management and Legacy Insurance businesses, today announces the appointment of Thomas (Tom) Solomon as Group Chief Financial Officer (CFO). Tom will also be appointed to the Company’s board of directors later in the year. Tom joins R&Q from his current position as Managing Director and Head of Americas Insurance Investment Banking at Bank of America. He has previously held senior positions at Citigroup and PricewaterhouseCoopers, LLP. Tom has an MBA in Finance and Economics from Columbia Business School and is a member of the Society of Actuaries. Tom will be based in R&Q’s New York office and report to William Spiegel, Group Deputy Executive Chairman.

 

ClearStar 48.2p £17.5m (CLSU.L)

The  provider of Human Capital Integrity℠ technology-based services specialising in background and medical screening, announces the launch of a testing service aimed at supporting employers with their COVID-19 return-to-work planning and keeping their workforce safe. The new service is provided by ClearStar’s Medical Information Services business through Clinical Reference Laboratory, Inc., one of the largest privately held clinical testing laboratories in the US, and it includes both an antibody and a diagnostic test. In the first instance, employees receive the CRL Clear™ kit, which is a dried blood spot finger prick test that is used to identify the presence, or lack, of COVID-19 antibodies in the blood, which are produced by the body in response to the virus. This includes IgA, IgM and IgG antibodies, which are produced at different stages of the immune system response. A positive test result indicates that the employee has been previously infected by COVID-19 and has developed antibodies that might provide the employee with immunity.

 

Begbies Traynor 105p £134m (BEG.L)

The business recovery, financial advisory and property services consultancy, announces an update on trading for its financial year ended 30 April 2020. Results broadly in line with market expectations: Revenue expected to be c.£70m (2019: £60.1m), adjusted PBT expected to be c.£9.2m (2019: £7.0m), having absorbed a £0.6m impact of the lockdown in the last six weeks of the financial year. “Looking ahead we remain well placed, given our strong financial position, the likely impact of the COVID-19 pandemic on the UK economy and the counter-cyclical focus of our business.”

 

MTI Wireless Edge 38.5p £33.8m (MWE.L)

The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors  announced that its subsidiary, Mottech Water Solutions Ltd, a provider of wireless irrigation control solutions, has signed an agreement to acquire its joint venture partner’s 40% holding in a joint venture it established in China in 2017. Following this acquisition, Mottech China is now a fully owned subsidiary of the Company. As announced in 2017, Mottech and its representative in China established this joint venture in order to pursue the Chinese market and now Mottech is strengthening its presence in this market.   China has become Mottech’s fastest growing market and the team are focused on supplying solutions to Chinese municipalities and large scale agricultural organisations as they seek to better manage their water resources and adapt to climate change. 

 

Kape Technologies 201p £311m (KAPE.L)

Kape has made a strong start to 2020, despite the global macroeconomic disruption caused by the COVID-19 pandemic. As announced on 31 March 2020, Kape has experienced increased demand for its products as working remotely has become commonplace across the globe in response to COVID-19. Within the Digital Privacy segment, new monthly sign-ups in April 2020 increased by 19% to the comparable period in 2019 on a proforma basis. The Company remains on track to deliver revenues of $120-123m and adjusted EBITDA1 of $35-38m in 2020. The integration of PIA continues to progress to plan and management are confident in delivering at least the $3.5-4.5m in cost synergies, as outlined at the time of the acquisition, in the current financial year.

 

Empyrean Energy 4.95p £23.3m (EME.L)

Results of its seismic inversion project, designed to assess the reservoir quality and reservoir rock composition at its Jade and Topaz prospects at Block 29/11 in the Pearl River Mouth Basin, offshore China. Reservoir rocks at Jade and Topaz interpreted to be excellent quality carbonates, porosities at Jade and Topaz interpreted to be in the highly favourable range of 20-30%, and an excellent cooperation between the Empyrean, COSL and CNOOC technical teams delivers a robust dataset resulting in significant technical confidence in the results.

 

NQ Minerals 6.75p £22.9m (AQSE:NQMI)

The base and precious metals producer from its Hellyer Gold Mine in Tasmania Australia announces that it has raised GBP189,500 (gross) at 7 and 7.5 pence per share from a UK based Institutional investor and a group of private investors for general working capital purposes. The Company is also planning to re-open the historic high-grade Beaconsfield Gold Mine in Tasmania, which has a JORC 2012 compliant Mineral Resource Estimate of 1.454 Mt at 10.3 g/t Au for 483,000 ounces of gold. 

 

Rutherford Health 227.5p £450m (AQSE:RUTH)

The Company has entered into a framework agreement with NHS Shared Business Services, under which it is able to provide cancer treatment services on demand by any NHS Trust at a pre-agreed set of prices. The agreement lasts for two years with an option to extend for a further two years on the agreement of both parties. The agreement covers the complete range of services that Rutherford offers, including radiotherapy, systemic anti-cancer therapy (chemotherapy), proton beam therapy and diagnostic services.

 

Feedback 1.05p £5.7m (FDBK.L)

The specialist medical imaging technology companytoday announces Royal Papworth Hospital NHS Foundation Trust has renewed its contract for clinical PACS (picture archiving and communication system) services with Feedback Medical Ltd, a wholly owned subsidiary of the Company.  The renewal will incorporate an upgrade to service, providing the Trust access to Bleepa®, Feedback’s flagship imaging-based communication platform. The contract, set for a term of 14 months, rel ates to Feedback’s Cadran PACS which has provided core medical imaging services to the Trust since 2001. The contract includes the use of Bleepa® as an upgrade to Cadran Web Viewer and will see Bleepa® made available to all clinicians at the Trust. For Feedback, the contract marks the second NHS site to adopt Bleepa® as a core imaging tool and is further recognition of the potential that Bleepa® has to enhance clinical care delivery. The first site was the Pennine Acute NHS Hospitals Trust which is using Bleepa® to support frontline staff to manage Covid-19 patients.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.